

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10595219	
	Filing Date		2006-11-16	
	First Named Inventor	David Helton		
	Art Unit			
	Examiner Name	Jean-Louis, Samira Jm		
	Attorney Docket Number		15513-1US	

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10595219
Filing Date		2006-11-16
First Named Inventor	David Helton	
Art Unit		
Examiner Name	Jean-Louis, Samira Jm	
Attorney Docket Number	15513-1US	

1	Ramesh NARAYANAN, et al. "Selective androgen receptor modulators in preclinical and clinical development", Nuclear Receptor Signaling, The Open Access Journal of the Nuclear Receptor Signaling Atlas, 2008, Vol. 6, 26 pgs.	<input type="checkbox"/>
2	BP Nutley, et al. "Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026, British Journal of Cancer (2005) 93, pgs. 1011-1018	<input type="checkbox"/>
3	H. Tecle, et al. "CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology", Pharmaceutica Acta Helvetiae 74 (2000) pgs. 141-148	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.